Table 6.
Table 3: Case series on IVTA for CRVO-ME
| Study (in chronological order) | # Eyes | IVTA dose (mg) | Follow up | Key outcomes |
|---|---|---|---|---|
| Batioglu 2007 | 20 Pts | 4 mg | 24 months | Mean CMT 49.2% of baseline value at 1-year follow up No change in VA IVTA improves short-term anatomy but recurrences and complications occur in long-term in non-ischemic CRVO |
| Moschos 2007 | 15 eyes | 4 mg | 12 months | Significant improvement in VA in non-ischemic CRVO lasted 6 months Decrease in macular thickness but with less significance at 12 months Significant improvements in foveal mfERG lasted 6 months Improvement in parafoveal mfERG but with less significance at 12 months Increase in IOP up to 6 months but returned to baseline at 1 year Effects of IVTA last maximum of 3 to 6 months |
| Goff 2006 | 29 eyes | 2 or 4 mg | 11.6 months | Improvement in VA 3 months post IVTA but final VA was same as baseline Elevated IOP in 5/22 patients Multiple injections resulted in better outcomes |
| Gregori 2006 | 40 eyes | 4 mg | 12 months | IVTA can improve VA in some but most return to baseline VA at 1 year despite repeated injections 50% received > 1 injection by 1 year IOP increased > or = 10 mmHg in 24% at 1 year with 2/12 requiring trabeculectomy |
| Williamson 2005 | 18 eyes | 2 mg | 12 months | 10patients required repeat injections Significant improvement in VA lasted for 6 months Significant decline in retinal thickness lasted for 3 months 11patients had rise in IOP 10 patients developed collateral circulation formation Beneficial effects of IVTA in non-ischemic CRVO transient |
| Ozdek 2005 | 22 eyes | 4 mg | Mean 11.5 2.4 | At least 3 lines of VA increase occurred in 81.8% of non-ischemic CRVO and 18.2% of ischemic CRVO Significant decrease in mean foveal thickness in both ischemic and non-ischemic CRVO at 9 months Although anatomical results similar in 2 groups, functional results are better in non-ischemic cases |
| Krepler 2005 | 13 eyes | 4 mg | 9 months | Significant improvement in VA in non-ischemic CRVO lasted for a maximum of 6 months Mean macular thickness significantly reduced until 9 months |
| Ip 2004 | 13 eyes | 4 mg | 6 months | Patients with non-ischemic CRVO had significant improvement in VA at 6 months while ischemic CRVO patients had non-statistically significant increase Decrease in mean foveal thickness 75% of patients with recurrence responded to retreatment No significant adverse effects |
| Park 2003 | 10 eyes | 4 mg | Mean 4.8 months | All non-ischemic CRVO cases showed significant improvement in CME by volumetric OCT Statistically significant increase in BCVA at end of study and 60% had VA of 20/50 or better 30% with history of glaucoma required treatment and 1 case with history of open angle glaucoma required trabeculectomy |
| Ip 2003 | 8 eyes | 4 mg | 3 months | Average gain in VA of 3.3 lines with 4/8 improving and 4/8 no change from baseline 7/8 had clinical resolution of ME No adverse effects |
BCVA: best corrected visual acuity
CME: cystoid macular edema
CMT: central macular thickness
CRVO: central retinal vein occlusion
IOP: intraocular pressure
IVTA: intravitreal triamcinolone
ME: macular edema
mfERG: multifocal electroretinography
OCT: optical coherence tomography
Pts: patients
VA: visual acuity